Jason’s Deli and The University of Texas MD Anderson Cancer Center proudly introduce the new Salmon Pacifica Salad as part of an ongoing alliance to raise money to help end cancer for patients and families around the world.
Now through April 2018, 50 cents from the sale of every Salmon Pacifica Salad at participating Jason’s Deli restaurants will be donated to MD Anderson to support cancer prevention research and programs.
To view the multimedia release go to:
https://www.multivu.com/players/English/8102251-jasons-deli-md-anderson-cancer-center-salmon-pacifica-salad/
HGTV’s top-rated reality competition, HGTV Design Star, will return for a fifth season beginning Sunday, June 13, at 10 p.m. ET/PT. Shot in New York City, the series will feature 12 creative finalists as they audition for their own show on HGTV. The finalists include Courtland Bascon, Los Angeles; Stacey Cohen, Chicago; Dan Faires, New York City; Nina Ferrer, New York City; Tera Hampton, Austin, Texas; Emily Henderson, Los Angeles; Trent Hultgren, Venice, Calif.; Julie Khuu, Santa Ana, Calif.; Michael Moeller, New York City; Casey Noble, Redondo Beach, Calif.; Alex Sanchez, Upper Marlboro, Md.; and Tom Vecchione, New York City. The series will air on Sundays for 11 weeks through August 22.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/hgtv/44162/
At Gundersen Lutheran Health System’s Bariatric Surgery Center, three bariatric surgeons perform about 150 weight-loss surgeries each year. With exceptional outcomes, Gundersen Lutheran has been named a Center of Excellence and Level 1 Accredited Bariatric Center*.
“When people are considering weight-loss surgery, they should know an organization’s success rates,” explains Gundersen Lutheran surgeon Shanu N. Kothari, MD. “We collect and carefully review data on our surgeries and change treatment based on outcomes.”
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/gundluth/49125/
The Leukemia & Lymphoma Society (LLS) today announced it has committed $40.3 million in new research investments to advance the most promising blood cancer science at leading academic and medical centers around the world, including Dana-Farber Cancer Institute in Boston; Weill Cornell Medicine and Memorial Sloan Kettering Cancer Center in New York; MD Anderson Cancer Center in Houston; Fondazione Centro San Raffaele in Milan; and South Australian Health & Medical Research Institute in Adelaide.
This $40.3 million investment, comprised of 75 new research grants in LLS’s portfolio of 300 projects, will fund a diverse array of research to find better treatments and cures for patients with leukemia, lymphoma, myeloma and other blood cancers.
To view the multimedia release go to:
http://www.multivu.com/players/English/7554855-lls-invests-millions-new-research-treatment-cures/
Researchers presenting at ASTRO 2015, the premier radiation oncology scientific event in the world, unveiled new data this week that could fundamentally change the way that early stage breast cancer is treated.
Results from a landmark prospective, randomized, multicenter phase III study conducted in Europe demonstrated that APBI brachytherapy leads to equivalent overall survival and local cancer control rates as compared to WBI after breast conserving surgery for selected patients with early stage breast cancers. These data were presented during the ASTRO official press conference and published in The Lancet, a leading high-impact global peer-reviewed medical journal.
“We have been confidently offering APBI brachytherapy to selected women for years based on numerous phase II, single site and large registry studies that have confirmed the clinical utility of site-specific radiation delivered in a condensed timeframe,” said Frank A. Vicini, M.D., radiation oncologist, 21st Century Oncology, Royal Oak, Mich. and contributing author to the 2009 and 2013 ASTRO and ABS APBI guidelines. “The results from this landmark, multicenter, prospective randomized clinical study are the first to offer the critical level one evidence necessary to drive the fundamental changes in breast conserving cancer treatment that patients and healthcare professionals have been demanding for years.”
To view the multimedia release go to:
http://www.multivu.com/players/uk/7661231-new-apbi-brachytherapy-data-at-astro-2015/
The average walker takes about 10,000 steps per day, which can put tremendous stress on the 26 bones and 33 joints in your feet. The Look for the “O” campaign from the American Orthopaedic Foot & Ankle Society (AOFAS) encourages consumers to take charge of their foot and ankle health and choose a foot and ankle orthopaedic surgeon when medical care is needed.
“Most people don’t give much thought to their foot health – that is, until something goes wrong,” stated J. Chris Coetzee, MD, president of the AOFAS Board of Directors. “But 75% of all people experience foot pain at some point in their lives, and it’s important to know how to find the best medical care before a problem arises.”
To view the multimedia release go to:
https://www.multivu.com/players/English/8164351-aofas-what-is-a-foot-and-ankle-orthopaedic-surgeon/
In an effort to promote science, technology, engineering and mathematics (STEM) education, the U.S. Army announced today that it has named the 2010 eCYBERMISSION national first-place teams. Managed by the U.S. Army Research, Development and Engineering Command (RDECOM) at Aberdeen Proving Ground, Md., the eCYBERMISSION program awarded more than $1 million to students from across the nation and in Department of Defense Education Activity schools overseas.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/ecybermission/44116/
The following statement is being issued by Block & Leviton LLP, Finkelstein Thompson LLP and Green & Noblin PC regarding the Drywall Antitrust Litigation.
If you purchased Wallboard INDIRECTLY from one or more of the companies listed below, your rights may be affected by proposed Settlements
Proposed class settlements totaling $10.5 million have been reached with two Defendants in In re Domestic Drywall Antitrust Litigation, MDL No. 2437 and 13-MD-2437, pending in the U.S. District Court for the Eastern District of Pennsylvania.
If you purchased for end use wallboard manufactured and/or distributed by CertainTeed Gypsum, Inc., USG Corporation, United States Gypsum Company, New NGC, Inc., Lafarge North America, Inc., Eagle Materials, Inc., American Gypsum Company LLC, PABCO Building Products, LLC, TIN, Inc., or their subsidiaries (collectively, the “Defendants”), between January 1, 2012 and November 30, 2014, you may be a class member. “Wallboard” means paper-backed gypsum wallboard, also called drywall or plasterboard.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7449651-drywall-class-action-settlement/
The following statement is being issued by Block & Leviton LLP, Finkelstein Thompson LLP and Green & Noblin PC regarding the Drywall Antitrust Litigation.
If you purchased Wallboard INDIRECTLY from one or more of the companies listed below, your rights may be affected by proposed Settlements
A proposed class settlement totaling $5.2 million has been reached with a defendant in In re Domestic Drywall Antitrust Litigation, MDL No. 2437 and 13-MD-2437, pending in the U.S. District Court for the Eastern District of Pennsylvania.
To view the multimedia release go to:
http://www.multivu.com/players/English/7975351-drywall-class-action-settlement/
The Leukemia & Lymphoma Society (LLS) today announced it has committed $28.6 million in new research investment to advance the most promising blood cancer science at leading academic and medical institutions around the world, including Dana-Farber Cancer Institute, Weill Cornell Medical College and MD Anderson Cancer Center. As LLS leads the charge to find cures for cancer patients, this new funding, along with ongoing investment in LLS’s aggressive research agenda, brings LLS’s total commitment to blood cancer research to more than $1 billion. The investment has led to the development of nearly every therapy currently used to treat the blood cancers.
Along with these new research grants, LLS remains committed to collaborating with biotechnology companies through its innovative Therapy Acceleration Program® (TAP), a model pioneered by LLS in the cancer arena in recognition that traditional research approaches weren’t yielding treatments and cures fast enough for patients. LLS commits approximately $13 million a year to its TAP initiatives. As part of the 24 current such collaborations, LLS recently initiated new investments with Kite Pharma and OncoPep.
To view the multimedia release go to:
http://www.multivu.com/players/English/7554852-lls-cancer-research-funding/
Time out! Did you know that more than 33 million adults in the United States1 – or one in six2 – deal with bladder control problems? Many women suffer in silence, frustrated with their current treatment but unaware that other options exist. This November, in observance of National Bladder Health Awareness Month, women around the country will take a Girls' Time Out to face the moments when they have struggled with bladder control problems. For more information, visit www.FacingOurMoments.com
To view Multimedia News Release, go to http://www.multivu.com/players/English/46562-medtronic-bladder-health-awareness-month-campaign/
Delta Air Lines (NYSE: DAL) is expanding the First Class cabin on more than 60 percent of its mainline domestic fleet – approximately 350 aircraft – as it responds to business customers’ requests for more premium cabin seating.
By summer 2013, Delta will add more than 1,200 First Class seats to its domestic MD-88, MD-90, Boeing 757-200 and Boeing 767-300 aircraft as it retrofits and upgrades the aircraft interiors. The initiative, which follows the addition of First Class cabins to all Delta Connection regional jets with more than 60 seats, does not impact Delta’s previously announced capacity guidance.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/delta/47794/
